• Published On : Jan-2015 |
  • Pages : 106 Pages |
  • Format :

Chapter 1 Preface

1.1 Report Description

1.2 Research Methodology

1.3 Assumptions

Chapter 2 Market Synopsis

Chapter 3 Porter’s Five Forces Analysis

3.1 Bargaining Power of Suppliers

3.2 Bargaining Power of Buyers

3.3 Threat of New Entrants

3.4 Threat of Substitutes

3.5 Intensity of Rivalry

Chapter 4 Industry Overview

4.1 Market Definition

4.2 Market Drivers

     4.2.1 Increasing prevalence of diabetes

     4.2.2 Globally rising obesity increasing the prevalence of diabetes

     4.2.3 Increasing R&D investments in drug discovery and development

     4.2.4 Rising awareness among people about diabetes and kidney-related disorders

4.3 Impact Analysis of Market Drivers

4.4 Market Restraints

     4.4.1 Strict regulatory requirements and long approval time for drugs

     4.4.2 Lack of comprehensive therapeutic management for diabetic nephropathy

4.5 Impact Analysis of Market Restraints

4.6 Market Trends

     4.6.1 Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market

Chapter 5 Global Market Size and Forecast

Chapter 6 Market Size and Forecast by Mode of Treatment

6.1 Disease Modifying Therapies

     6.1.1 Angiotensin-Converting Enzyme Inhibitors

     6.1.2 Angiotensin Receptor Blockers

     6.1.3 Diuretics

     6.1.4 Calcium Channel Blockers

     6.1.5 Renin Inhibitors

     6.1.6 Connective Tissue Growth Factor Inhibitors

     6.1.7 Antioxidant Inflammation Modulator

     6.1.8 Monocyte Chemoattractant Proteins Inhibitor

     6.1.9 Endothelin-A Receptor Antagonist

     6.1.10 G Protein-Coupled Receptors

Chapter 7 Market Size and Forecast by Geography

7.1 North America

     7.1.1 Scenario in the U.S.

     7.1.2 Scenario in Canada

7.2 Europe

     7.2.1 Scenario in Germany

     7.2.2 Scenario in France

     7.2.3 Scenario in the U.K.

7.3 Asia

     7.3.1 Scenario in Japan

     7.3.2 Scenario in China

     7.3.3 Scenario in India

Chapter 8 Pipeline Drugs for Diabetic Nephropathy

8.1 Drugs Under Development for Diabetic Nephropathy

Chapter 9 Competitive Scenario

9.1 Competitive Benchmarking

Chapter 10 Company Profiles

10.1 Novartis AG

     10.1.1 Company overview

     10.1.2 Products and services

     10.1.3 Financial performance

     10.1.4 Key developments

10.2 Merck & Co., Inc.

     10.2.1 Company overview

     10.2.2 Products and services

     10.2.3 Financial performance

     10.2.4 Key developments

10.3 Pfizer, Inc.

     10.3.1 Company overview

     10.3.2 Products and services

     10.3.3 Financial performance

     10.3.4 Key developments

10.4 Abbott Laboratories

     10.4.1 Company overview

     10.4.2 Products and services

     10.4.3 Financial performance

     10.4.4 Key developments

10.5 Sanofi

     10.5.1 Company overview

     10.5.2 Products and services

     10.5.3 Financial performance

     10.5.4 Key developments

10.6 Eli Lilly and Company

     10.6.1 Company overview

     10.6.2 Products and segments

     10.6.3 Financial performance

     10.6.4 Key developments

10.7 Reata Pharmaceuticals, Inc.

     10.7.1 Company overview

     10.7.2 Products and segments

     10.7.3 Financial performance

     10.7.4 Key developments

10.8 Bayer AG

     10.8.1 Company overview

     10.8.2 Products and segments

     10.8.3 Financial performance

     10.8.4 Key developments

10.9 AbbVie, Inc.

     10.9.1 Company overview

     10.9.2 Products and segments

     10.9.3 Financial performance

     10.9.4 Key developments

10.10 Mitsubishi Tanabe Pharma Corporation

     10.10.1 Company overview

     10.10.2 Products and segments

     10.10.3 Financial performance

     10.10.4 Key developments


List of Tables

TABLE 1 Market Snapshot: Diabetic nephropathy market, 2014 and 2020

TABLE 2 Drivers for diabetic nephropathy market: Impact analysis

TABLE 3 Estimated average timelines for clinical trial approval in various countries

TABLE 4 Restraints for diabetic nephropathy market: Impact analysis

TABLE 5 Global diabetic nephropathy market size, by region, 2010 – 2013 (USD thousand)

TABLE 6 Global diabetic nephropathy market size, by region, 2014 – 2020 (USD thousand)

TABLE 7 Global diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 8 Global diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 9 Global DMT market size, by region, 2010 – 2013 (USD thousand)

TABLE 10 Global DMT market size, by region, 2014 – 2020 (USD thousand)

TABLE 11 Global DMT market size, by drug categories, 2010 – 2013 (USD thousand)

TABLE 12 Global DMT market size, by drug categories, 2014 – 2020 (USD thousand)

TABLE 13 Global ACE inhibitors market size, by region, 2010 – 2013 (USD thousand)

TABLE 14 Global ACE inhibitors market size, by region, 2014 – 2020 (USD thousand)

TABLE 15 Global ARBs market size, by region, 2010 – 2013 (USD thousand)

TABLE 16 Global ARBs market size, by region, 2014 – 2020 (USD thousand)

TABLE 17 Global diuretics market size, by region, 2010 – 2013 (USD thousand)

TABLE 18 Global diuretics market size, by region, 2014 – 2020 (USD thousand)

TABLE 19 Global CCBs market size, by region, 2010 – 2013 (USD thousand)

TABLE 20 Global CCBs market size, by region, 2014 – 2020 (USD thousand)

TABLE 21 Global renin inhibitors market size, by region, 2010 – 2013 (USD thousand)

TABLE 22 Global renin inhibitors market size, by region, 2014 – 2020 (USD thousand)

TABLE 23 Global CTGF inhibitors market size, by region, 2010 – 2013 (USD thousand)

TABLE 24 Global CTGF inhibitors market size, by region, 2014 – 2020 (USD thousand)

TABLE 25 Global AIM market size, by region, 2010 – 2013 (USD thousand)

TABLE 26 Global AIM market size, by region, 2014 – 2020 (USD thousand)

TABLE 27 Global MCP inhibitors market size, by region, 2010 – 2013 (USD thousand)

TABLE 28 Global MCP inhibitors market size, by region, 2014 – 2020 (USD thousand)

TABLE 29 Global ETAR market size, by region, 2010 – 2013 (USD thousand)

TABLE 30 Global ETAR market size, by region, 2014 – 2020 (USD thousand)

TABLE 31 Global GPCRs market size, by region, 2010 – 2013 (USD thousand)

TABLE 32 Global GPCRs market size, by region, 2014 – 2020 (USD thousand)

TABLE 33 The North American diabetic nephropathy market size, by country, 2010 – 2013 (USD thousand)

TABLE 34 The North American diabetic nephropathy market size, by country, 2014 – 2020 (USD thousand)

TABLE 35 The U.S. diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 36 The U.S. diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 37 The Canadian diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 38 The Canadian diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 39 The European diabetic nephropathy market size, by country, 2010 – 2013 (USD thousand)

TABLE 40 The European diabetic nephropathy market size, by country, 2014 – 2020 (USD thousand)

TABLE 41 The German diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 42 The German diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 43 The French diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 44 The French diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 45 The U.K. diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 46 The U.K. diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 47 The Asian diabetic nephropathy market size, by country, 2010 – 2013 (USD thousand)

TABLE 48 The Asian diabetic nephropathy market size, by country, 2014 – 2020 (USD thousand)

TABLE 49 The Japanese diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 50 The Japanese diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 51 The Chinese diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 52 The Chinese diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 53 The Indian diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand)

TABLE 54 The Indian diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand)

TABLE 55 Major pipeline drugs for diabetic nephropathy

TABLE 56 Product categories of Novartis AG

TABLE 57 Product categories of Merck & Co., Inc.

TABLE 58 Product categories of Pfizer, Inc.

TABLE 59 Product categories of Abbott Laboratories

TABLE 60 Product categories of Sanofi

TABLE 61 Product segments of Eli Lilly and Company

TABLE 62 Product categories of Reata Pharmaceuticals, Inc.

TABLE 63 Product categories of Bayer AG

TABLE 64 Product categories of AbbVie, Inc.

TABLE 65 Product categories of Mitsubishi Tanabe Pharma Corporation


List of Figures 

FIG. 1 Diabetic nephropathy market: Porter’s five forces analysis

FIG. 2 Major DMT for diabetic nephropathy

FIG. 3 Number of people with diabetes mellitus (20 – 79 years) in major countries, 2010, and 2030 (million)

FIG. 4 Prevalence of overweight and obese males aged 30 years and above, 2005 and 2015 (%)

FIG. 5 Prevalence of overweight and obese females aged 30 years and above, 2005 and 2015 (%)

FIG. 6 Global diabetic nephropathy market share, by region, by value, 2013

FIG. 7 Global diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 8 Global DMT market share, by region, by value, 2013 30

FIG. 9 Global DMT market share, by disease categories, by value, 2013

FIG. 10 Global ACE inhibitors market share, by region, by value, 2013

FIG. 11 Global ARBs market share, by region, by value, 2013

FIG. 12 Global diuretics market share, by region, by value, 2013

FIG. 13 Global CCBs market share, by region, by value, 2013

FIG. 14 Global renin inhibitors market share, by region, by value, 2013

FIG. 15 Global CTGF inhibitors market share, by region, by value, 2013

FIG. 16 Global AIM market share, by region, by value, 2013

FIG. 17 Global MCP inhibitors market share, by region, by value, 2013

FIG. 18 Global ETAR market share, by region, by value, 2013

FIG. 19 Global GPCRs market share, by region, by value, 2013

FIG. 20 The North American diabetic nephropathy market share, by country, by value, 2013

FIG. 21 The U.S. diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 22 The Canadian diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 23 The European diabetic nephropathy market share, by country, by value, 2013

FIG. 24 The German diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 25 The French diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 26 The U.K. diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 27 The Asian diabetic nephropathy market share, by country, by value, 2013

FIG. 28 The Japanese diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 29 The Chinese diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 30 The Indian diabetic nephropathy market share, by mode of treatment, by value, 2013

FIG. 31 Competitive landscape of diabetic nephropathy market, 2013

FIG. 32 Novartis AG’s net sales and net income, 2011 – 2013 (USD million)

FIG. 33 Merck & Co., Inc.’s sales and net income, 2011 – 2013 (USD million)

FIG. 34 Pfizer, Inc.’s revenue and net income, 2011 – 2013 (USD million)

FIG. 35 Abbott Laboratories’ net sales and net earnings, 2011 – 2013 (USD million)

FIG. 36 Sanofi’s net sales and net income, 2011 – 2013 (USD million)

FIG. 37 Eli Lilly and Company’s revenue and net income, 2011 – 2013 (USD million)

FIG. 38 Bayer AG’s net sales and net income, 2011 – 2013 (USD million)

FIG. 39 AbbVie, Inc.’s net sales and net earnings, 2011 – 2013 (USD million)

FIG. 40 Mitsubishi Tanabe Pharma Corporation’s net sales and net earnings, 2011 – 2013 (USD million)